Showing results (101-110 of 208) with videos related to

Sort By:
Pageof 21
Zeitschrift Fur Rheumatologie|August 19, 2016
[Digital ulcers in systemic sclerosis : A retrospective heath service study analysing treatment with bosentan and other vasoactive therapies]G Riemekasten, S Beissert, J H W Distler, et al.
Zeitschrift Fur Rheumatologie|February 5, 2019
[Multimodal rheumatologic complex treatment of rheumatoid arthritis-a monocentric retrospective analysis]P Klemm, O Hudowenz, T Asendorf, et al.
Glia|October 1, 1996
Chronic complement C3 gene expression in the CNS of transgenic mice with astrocyte-targeted interleukin-6 expressionS R Barnum, J L Jones, U Müller-Ladner, et al.
British Journal of Rheumatology|February 4, 1998
Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugsR H Straub, U Müller-Ladner, T Lichtinger, et al.
Zeitschrift Fur Rheumatologie|June 29, 2006
[Evidence-based therapy of Raynaud's syndrome]M Distler, J Distler, A Ciurea, et al.
European Journal of Medical Research|November 21, 2007
Pathologic alterations of the heart and the kidney in patients with ankylosing spondylitisU Lange, G Stapfer, T Ditting, et al.
Diabetes, Obesity & Metabolism|July 30, 2005
Caucasian patients with type 2 diabetes mellitus have elevated levels of monocyte chemoattractant protein-1 that are not influenced by the -2518 A-->G promoter polymorphismB Zietz, C Büchler, H Herfarth, et al.
FEBS Letters|June 14, 2003
Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetesB Zietz, H Herfarth, G Paul, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|July 9, 2004
Identification of influencing variables on adiponectin serum levels in diabetes mellitus type 1 and type 2A Schäffler, H Herfarth, G Paul, et al.
Arthritis and Rheumatism|January 11, 2005
Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumabT Bongartz, P Härle, S Friedrich, et al.
Pageof 21